IGEN International Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IGEN International

IGEN 0.0001000

0.0%

Mar 7 3:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Paul Lee who wrote (749)	1/10/2002 3:47:38 PM
From: Biomaven	Read Replies (1) of 1025

The key here is that the right to cancel the license is likely worth considerably more than the $501m damages. Roche has $500m/yr in sales of products dependent on the IGEN license, and these are all in jeopardy. Diagnostics has been Roche's sole bright spot and they can't just abandon it. This will likely force a settlement before appeal. Igen has agreed not to pull the license during the pendency of the appeal, but I don't think Roche can afford to let the cancellation threat hang out there for the year's duration of an appeal. This is my second-biggest position, so I'm pretty delighted by this verdict. I can't pretend to have predicted this actual outcome - I was sure all along that Roche would settle before the verdict to prevent the possible loss of its license. Peter P.S. Here's my view of the stock about 18 months ago: Message 13772615

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next